Form 4: Compass Therapeutics Executive Granted Stock Options

Jonathan Anderman, Sr VP, Gen Counsel & Corp Sec of Compass Therapeutics, was granted stock options for 280,000 shares on February 11, 2025.

Summary

• On February 11, 2025, Jonathan Anderman, the Sr VP, Gen Counsel & Corp Sec of Compass Therapeutics, received stock options for 280,000 shares.
• The exercise price of these options is $3.65 per share.
• The options vest in 48 substantially equal monthly installments beginning on March 11, 2025.
• The options expire on February 11, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and suggests confidence in the executive's ability to contribute to the company's success. There are no red flags or negative information in the document.

Positives

• The granting of stock options to a key executive aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives. This grant is typical for a company of Compass Therapeutics' size and stage.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Comparable companies like CRISPR Therapeutics and Editas Medicine also utilize stock options to incentivize their leadership teams.
• The size of the grant is within the typical range for a senior executive at a company with a similar market capitalization to Compass Therapeutics.

Stakeholder Impact

• Shareholders may view the option grant as a positive sign, aligning management's interests with theirs.
• Employees may see this as a sign of stability and potential growth for the company.

Key Dates